In-silico Leishmania target selectivity of antiparasitic terpenoids

Molecules

Volumn 18, Issue 7, 2013, Pages 7761-7847

  Ogungbe, Ifedayo Victor ^a   Setzer, William N ^b  

^a JACKSON STATE UNIVERSITY   (United States)

^b University of Alabama in Huntsville   (United States)

Author keywords

Antileishmanial activity; Docking; Drug targets; Leishmania; Terpenoids

Indexed keywords

ANTITRYPANOSOMAL AGENT; DIHYDROOROTATE DEHYDROGENASE; DITERPENE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; LIMONOID; METHIONINE TRANSFER RNA LIGASE; OXIDOREDUCTASE; TERPENE; WITHANOLIDE;

ARTICLE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; LEISHMANIA; LEISHMANIASIS; MOLECULAR DOCKING; DRUG EFFECTS;

DITERPENES; DRUG DESIGN; GLYCEROLPHOSPHATE DEHYDROGENASE; LEISHMANIA; LEISHMANIASIS; LIMONINS; METHIONINE-TRNA LIGASE; MOLECULAR DOCKING SIMULATION; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; TERPENES; TRYPANOCIDAL AGENTS; WITHANOLIDES;

EID: 84880847937     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18077761     Document Type: Article

References (97)

1. WHO Technical Report Series 949, 2010. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases. Available online: http://apps.who.int/iris/bitstream/10665/44412/1/WHO-TRS-949-eng.pdf (accessed on 15 April 2013).
2. Barrett, M.P.; Mottram, J.C.; Goombs, G.H. Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Trends Microbiol. 1999, 7, 82-88.
3. Chawla, B.; Madhubala, R. Drug targets in Leishmania. J. Parasit. Dis. 2010, 34, 1-13.
4. Crowther, G.J.; Shanmugam, D.; Carmona, S.J.; Doyle, M.A.; Herz-Fowler, C.; Berriman, M.; Nwaka, S.; Ralph, S.A.; Roos, D.S.; Van Voorhis, W.C.; et al. Identification of attractive drug targets in neglected disease pathogens using an in silico approach. PLoS Negl. Trop. Dis. 2010, 4, e804.
5. Schmidt, T.J.; Khalid, S.A.; Romanha, A.J.; Alves, T.M.A.; Biavatti, M.W.; Brun, R.; Da Costa, F.B.; de Castro, S.L.; Ferreira, V.F.; de Lacerda, M.V.G.; et al. The potential of secondary metabolites from plants as drugs or leads against protozoan neglected ideases-Part I. Curr. Med. Chem. 2012, 19, 2128-2175.
6. Rigden, D.J.; Phillips, S.E.V.; Michels, P.A.M.; Fothergill-Gilmore, L.A. The structure of pyruvate kinase from Leishmania mexicana reveals details of the allosteric transition and unusual effector specificity. J. Mol. Biol. 1999, 291, 615-635.
7. Morgan, H.P.; Walsh, M.J.; Blackburn, E.A.; Wear, M.A.; Boxer, M.B.; Shen, M.; Veith, H.; McNae, I.W.; Nowicki, M.W.; Michels, P.A.; et al. A new family of covalent inhibitors block nucleotide binding to the active site of pyruvate kinase. Biochem. J. 2012, 448, 67-72.
8. Cordeiro, A.T.; Michels, P.A.; Delboni, L.F.; Thiemann, O.H. The crystal structure of glucose-6- phosphate isomerase from Leishmania mexicana reveals novel active site features. Eur. J. Biochem. 2004, 271, 2765-2772.
9. Arsenieva, D.; Appavu, B.L.; Mazock, G.H.; Jeffery, C.J. Crystal structure of phosphoglucose isomerase from Trypanosoma brucei complexed with glucose-6-phosphate at 1.6 Å resolution. Proteins 2008, 74, 72-80.
10. Steiner, T.; Lamerz, A.C.; Hess, P.; Breithaupt, C.; Krapp, S.; Bourenkov, G.; Huber, R.; Gerardy-Schahn, R.; Jacob, U. Open and closed structures of the UDP-glucose pyrophosphorylase from Leishmania major. J. Biol. Chem. 2007, 282, 13003-13010.
11. Kim, H.; Hol, W.G. Crystal structure of Leishmania mexicana glycosomal glyceraldehyde-3- phosphate dehydrogenase in a new crystal form confirms the putative physiological active site structure. J. Mol. Biol. 1998, 278, 5-11.
12. Guido, R.V.C.; Oliva, G.; Montanari, C.A.; Andricopulo, A.D. Structural basis for selective inhibition of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase: Molecular docking and 3D QSAR studies. J. Chem. Inf. Model. 2008, 48, 918-929.
13. Zhang, W.W.; McCall, L.I.; Matlashewski, G. Role of cytosolic glyceraldehyde-3-phosphate dehydrogenase in visceral organ infection by Leishmania donovani. Eukaryot. Cell 2013, 12, 70-77.
14. Suresh, S.; Turley, S.; Opperdoes, F.R.; Michels, P.A.; Hol, W.G. A potential target enzyme for trypanocidal drugs revealed by the crystal structure of NAD-dependent glycerol-3-phosphate dehydrogenase from Leishmania mexicana. Structure 2000, 8, 541-552.
15. Choe, J.; Guerra, D.; Michels, P.A.; Hol, W.G. Leishmania mexicana glycerol-3-phosphate dehydrogenase showed conformational changes upon binding a bi-substrate adduct. J. Mol. Biol. 2003, 329, 335-349.
16. Olivares-Illana, V.; Pérez-Montfort, R.; López-Calahorra, F.; Costas, M.; Rodríguez-Romero, A.; Tuena de Gómez-Puyou, M.; Gómez-Puyou, A. Structural differences in triosephosphate isomerase from different species and discovery of a multitrypanosomatid inhibitor. Biochemistry 2006, 45, 2556-2560.
17. Alahuhta, M.; Wierenga, R.K. Atomic resolution crystallography of a complex of triosephosphate isomerase with a reaction-intermediate analog: New insight in the proton transfer reaction mechanism. Proteins 2010, 78, 1878-1888.
18. Kumar, K.; Bhargava, P.; Roy, U. Cloning, overexpression and characterization of Leishmania donovani triosephosphate isomerase. Exp. Parasitol. 2012, 130, 430-436.
19. Fyfe, P.K.; Westrop, G.D.; Silva, A.M.; Coombs, G.H.; Hunter, W.N. Leishmania TDR1 structure, a unique trimeric glutathione transferase capable of deglutathionylation and antimonial prodrug activation. Proc. Natl. Acad. Sci. USA 2012, 109, 11693-11698.
20. Garami, A.; Mehlert, A.; Ilg, T. Glycosylation defects and virulence phenotypes of Leishmania mexicana phosphomannomutase and dolicholphosphate- mannose synthase gene deletion mutants. Mol. Cell Biol. 2001, 21, 8168-8183.
21. Silva, M.S.; Barata, L.; Ferreira A.E.N.; Romão, S.; Tomás, A.M.; Freire, A.P.; Cordeiro, C. Catalysis and structural properties of Leishmania infantum glyoxalase II: Trypanothione specificity and phylogeny. Biochemistry 2008, 47, 195-204.
22. Padmanabhan, P.K.; Mukherjee, A.; Madhubala, R. Characterization of the gene encoding glyoxalase II from Leishmania donovani: A potential target for anti-parasite drugs. Biochem. J. 2006, 393, 227-234.
23. Silva, M.S.; Ferreira, A.E.N.; Tomás, A.M.; Cordeiro, C.; Freire, A.P. Quantitative assessment of the glyoxalase pathway in Leishmania infantum as a therapeutic target by modeling and computer simulation. FEBS J. 2005, 272, 2388-2398.
24. Sajid, M.; McKerrow, J.H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 2002, 120, 1-21.
25. Paladi, C.D.S.; Pimentel, I.A.; Katz, S.; Cunha, R.L.; Judice, W.A.; Caires, A.C.; Barbiéri, C.L. In vitro and in vivo activity of a palladacycle complex on Leishmania (Leishmania) amazonensis. PLoS Negl. Trop. Dis. 2012, 6, e1626.
26. Coetzer, T.H.T.; Goldring, J.P.D.; Huson, L.E.J. Oligopeptidase B: A processing peptidase involved in pathogenesis. Biochemie 2008, 90, 336-344.
27. McLuskey, K.; Paterson, N.G.; Bland, N.D.; Isaacs, N.W.; Mottram, J.C. Crystal structure of Leishmania major oligopeptidase B gives insight into the enzymatic properties of a trypanosomatid virulence factor. J. Biol. Chem. 2010, 285, 39249-39259.
28. Swenerton, R.K.; Zhang, S.; Sajid, M.; Medzihradszky, K.F.; Craik, C.S.; Kelly, B.L.; McKerrow, J.H. The oligopeptidase B of Leishmania regulates parasite enolase and immune evasion. J. Biol. Chem. 2011, 286, 429-240.
29. Cordeiro, A.T.; Feliciano, P.R.; Pinkeiro, M.P.; Nonato, M.C. Crystal structure of dihydroorotate dehydrogenase from Leishmania major. Biochemie 2012, 94, 1739-1748.
30. Pinheiro, M.P.; Emery, F.D.S.; Nonato, M.C. Target sites for the design of anti-trypanosomatid drugs based on the structure of dihydroorotate dehydrogenase. Curr. Pharm. Des. 2013, 19, 2615-2627.
31. Camacho, A.; Hidalgo-Zarco, F.; Bernier-Villamor, V.; Ruiz-Pérez, L.M.; González-Pacanowska, D. Properties of Leishmania major dUTP nucleotidohydrolase, a distinct nucleotide-hydrolysing enzyme in kinetoplastids. Biochem. J. 2000, 346, 163-168.
32. Nguyen, C.; Kasinathan, G.; Leal-Cortijo, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz-Pérez, L.M.; Johansson, N.G.; González- Pacanowska, D.; Gilbert, I.H. Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target. J. Med. Chem. 2005, 48, 5942-5954.
33. Hemsworth, G.R.; Moroz, O.V.; Fogg, M.J.; Scott, B.; Bosch-Navarrete, C.; González-Pacanowska, D.; Wilson, K.S. The crystal structure of the Leishmania major deoxyuridine triphosphate nucleotidohydrolase in complex with nucleotide analogues, dUMP, and deoxyuridine. J. Biol. Chem. 2011, 286, 16470-16481.
34. Gazanion, E.; Garcia, D.; Silvestre, R.; Gérard, C.; Guichou, J.F.; Labesse, G.; Seveno, M.; Cordeiro-Da-Silva, A.; Ouaissi, A.; Sereno, D.; et al. The Leishmania nicotinamidase is essential for NAD+ production and parasite proliferation. Mol. Microbiol. 2011, 82, 21-38.
35. Shi, W.; Schramm, V.L.; Almo, S.C. Nucleoside hydrolase from Leishmania major. Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-Å crystal structure. J. Biol. Chem. 1999, 274, 21114-21120.
36. Cui, L.; Rajasekariah, G.R.; Martin, S.K. A nonspecific nucleoside hydrolase from Leishmania donovani: Implications for purine salvage by the parasite. Gene 2001, 280, 153-162.
37. Rennó, M.N.; França, T.C.; Nico, D.; Palatnik-de-Sousa, C.B.; Tinoco, L.W.; Figueroa-Villar, J.D. Kinetics and docking studies of two potential new inhibitors of the nucleoside hydrolase from Leishmania donovani. Eur. J. Med. Chem. 2012, 56, 301-307.
38. Souza, T.A.C.B.; Trindade, D.M.; Tonoli, C.C.C.; Santos, C.R.; Ward, R.J.; Arni, R.K.; Oliveira, A.H.C.; Murakami, M.T. Molecular adaptability of nucleoside diphosphate kinase b from trypanosomatid parasites: Stability, oligomerization and structural determinants of nucleotide binding. Mol. BioSyst. 2011, 7, 2189-2195.
39. Seebeck, T.; Gong, K.W.; Kunz, S.; Schaub, R.; Shalaby, T.; Zorghi, R. cAMP signaling in Trypanosoma brucei. Int. J. Parasitol. 2001, 31, 491-498.
40. Wang, H.; Yan, Z.; Geng, J.; Kunz, S.; Seebeck, T.; Ke, H. Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors. Mol. Microbiol. 2007, 66, 1029-1038.
41. Malki-Feldman, L.; Jaffe, C.L. Leishmania major: Effect of protein kinase A and phosphodiesterase activity on infectivity and proliferation of promastigotes. Exp. Parasitol. 2009, 123, 39-44.
42. Nare, B.; Luba, J.; Hardy, L.W.; Beverly, S. New approaches to Leishmania chemotherapy: Pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity. Parasitology 1997, 114, S101-S110.
43. Gourley, D.G.; Schüttelkopf, A.W.; Leonard, G.A.; Luba, J.; Hardy, L.W.; Beverley, S.M.; Hunter, W.N. Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites. Nat. Struct. Biol. 2001, 8, 521-525.
44. Kaur, J.; Kumar, P.; Tyagi, S.; Pathak, R.; Batra, S.; Singh, P.; Singh, N. In silico screening, structure-activity relationship, and biologic evaluation of selective pteridine reductase inhibitors targeting visceral leishmaniasis. Antimicrob. Agents Chemother. 2011, 55, 659-666.
45. Guerrieri, D.; Ferrari, S.; Costi, M.P.; Michels, P.A. Biochemical effects of riluzole on Leishmania parasites. Exp. Parasitol. 2013, 133, 250-254.
46. Price, H.P.; Menon, M.R.; Panethymitaki, C.; Goulding, D.; McKean, P.G.; Smith, D.F. Myristoyl-CoA: Protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. J. Biol. Chem. 2003, 278, 7206-7214.
47. Frearson, J.A.; Brand, S.; McElroy, S.P.; Cleghorn, L.A.; Smid, O.; Stojanovski, L.; Price, H.P.; Guther, M.L.; Torrie, L.S.; Robinson, D.A.; et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 2010, 464, 728-732.
48. Brannigan, J.A.; Smith, B.A.; Yu, Z.; Brzozowski, A.M.; Hodgkinson, M.R.; Maroof, A.; Price, H.P.; Meier, F.; Leatherbarrow, R.J.; Tate, E.W.; et al. N-myristoyltransferase from Leishmania donovani: Structural and functional characterisation of a potential drug target for visceral leishmaniasis. J. Mol. Biol. 2010, 396, 985-999.
49. Venugopal, V.; Sen, B.; Datta, A.K.; Banerjee, R. Structure of cyclophilin from Leishmania donovani at 1.97 Å resolution. Acta Crystallogr. Sect. F 2007, F63, 60-64.
50. Yau, W.L.; Blisnick, T.; Taly, J.F.; Helmer-Citterich, M.; Schiene-Fischer, C.; Leclercq, O.; Li, J.; Schmidt-Arras, D.; Morales, M.A.; Notredame, C.; et al. Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability. PLoS Negl. Trop. Dis. 2010, 4, e729.
51. Larson, E.T.; Kim, J.E.; Zucker, F.H.; Kelley, A.; Mueller, N.; Napuli, A.J.; Verlinde, C.L.M.J.; Fan, E.; Buckner, F.S.; Van Voorhis, W.C.; et al. Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. Biochemie 2011, 93, 570-582.
52. Larson, E.T.; Kim, J.E.; Castaneda, L.J.; Napuli, A.J.; Zhang, Z.; Fan, E.; Zucker, F.H.; Verlinde, C.L.; Buckner, F.S.; Van Voorhis, W.C.; et al. The double-length tyrosyl-tRNA synthetase from the eukaryote Leishmania major forms an intrinsically asymmetric pseudo-dimer. J. Mol. Biol. 2011, 3, 159-176.
53. Chan-Bacab, M.J.; Peña-Rodríguez, LM. Plant natural products with leishmanicidal activity. Nat. Prod. Rep. 2001, 18, 674-688.
54. Rocha, L.G.; Almeida, J.R.G.S.; Macêdo, R.O.; Barbosa-Filho, J.M. A review of natural products with antileishmanial activity. Phytomedicine 2005, 12, 514-535.
55. Salem, M.M.; Werbovetz, K.A. Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis. Curr. Med. Chem. 2006, 13, 2571-2598.
56. Polonio, T.; Efferth, T. Leishmaniasis: Drug resistance and natural products (Review). Int. J. Mol. Med. 2008, 22, 277-286.
57. Mishra, B.B.; Singh, R.K.; Strivastava, A.; Tripathi, V.J.; Tiwari, V.K. Fighting against leishmaniasis: Search of alkaloids as future true potential anti-leishmanial agents. Mini-Rev. Med. Chem. 2009, 9, 107-123.
58. Sen, R.; Chatterjee, M. Plant derived therapeutics for the treatment of leishmaniasis. Phytomedicine 2011, 18, 1056-1069.
59. Ogungbe, I.V.; Singh, M.; Setzer, W.N. Antileishmanial natural products from plants. Stud. Nat. Prod. Chem. 2012, 36, 331-382.
60. Schmidt, T.J.; Khalid, S.A.; Romanha, A.J.; Alves, T.M.A.; Biavatti, M.W.; Brun, R.; Da Costa, F.B.; de Castro, S.L.; Ferreira, V.F.; de Lacerda, M.V.G.; et al. The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases-Part II. Curr. Med. Chem. 2012, 19, 2176-2228.
61. Monzote, L.; Alarcón, O.; Setzer, W.N. Antiprotozoal activity of essential oils. Agric. Consp. Sci. 2012, 77, 167-175.
62. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A.J. Recent developments in fragment-based drug discovery. J. Med. Chem. 2008, 51, 3661-3680.
63. Zoete, V.; Grosdidier, A.; Michielin, O. Docking, virtual high throughput screening and in silico fragment-based drug design. J. Cell Mol. Med. 2009, 13, 238-248.
64. Lekphrom, R.; Kanokmedhakul, S.; Kanokmedhakul, K. Bioactive diterpenes from the aerial parts of Anisochilus harmandii. Planta Med. 2010, 76, 726-728.
65. Yuan, T.; Zhu, R.X.; Zhang, H.; Odeku, O.A.; Yang, S.P.; Liao, S.G.; Yue, J.M. Structure determination of grandifotane A from Khaya grandifoliola by NMR, X-ray diffraction, and ECD calculation. Org. Lett. 2010, 12, 252-255.
66. Idowu, O.A.; Soniran, O.T.; Ajana, O.; Aworinde, D.O. Ethnobotanical survey of antimalarial plants used in Ogun State, southwest Nigeria. Afr. J. Pharm. Pharmacol. 2010, 4, 55-60.
67. Bickii, J.; Njifutie, N.; Foyere, J.A.; Basco, L.K.; Ringwald, P. In vitro antimalarial activity of limonoids from Khaya grandifoliola C.D.C. (Meliaceae). J. Ethnopharmacol. 2000, 69, 27-33.
68. Sartorelli, P.; Andrade, S.P.; Melhem, M.S.C.; Prado, F.O.; Tempone, A.G. Isolation of antileishmanial sterol from the fruits of Cassia fistula using bioguided fractionation. Phytother. Res. 2007, 21, 644-647.
69. Hoet, S.; Pieters, L.; Muccioli, G.G.; Habib-Jiwan, J.L.; Opperdoes, F.R.; Quetin-Leclercq, J. Antitrypanosomal activity of triterpenoids and sterols from the leaves of Strychnos spinosa and related compounds. J. Nat. Prod. 2007, 70, 1360-1363.
70. Nweze, N.E.; Anene, B.M.; Asuzu, I.U. In vitro anti-trypanosomal activities of crude extracts, b-sitosterol and α-sulfur from Buchholzia coriacea seed. Afr. J. Biotechnol. 2011, 10, 15626-15632.
71. Setzer, W.N.; Ogungbe, I.V. In-silico investigation of antitrypanosomal phytochemicals from Nigerian medicinal plants. PLoS Negl. Trop. Dis. 2012, 6, e1727.
72. Kerr, I.D.; Wu, P.; Marion-Tsukamaki, R.; Mackey, Z.B.; Brinen, L.S. Crystal structures of TbCatB and rhodesain, potential chemotherapeutic targets and major cysteine proteases of Trypanosoma brucei. PLoS Negl. Trop. Dis. 2010, 4, e701.
73. Cordeiro, A.T.; Feliciano, P.R.; Nonato, M.C. Crystal structure of Leishmania major dihydroorotate dehydrogenase. Biochimie 2012, doi:10.2210/pdb3gye/pdb.
74. Cheleski, J.; Rocha, J.R.; Pinheiro, M.P.; Wiggers, H.J.; da Silva, A.B.F.; Nonato, M.C.; Montanari, C.A. Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery. Eur. J. Med. Chem. 2010, 45, 5899-5909.
75. Brand, S.; Cleghorn, L.A.; McElroy, S.P.; Robinson, D.A.; Smith, V.C.; Hallyburton, I.; Harrison, J.R.; Norcross, N.R.; Spinks, D.; Bayliss, T.; et al. Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J. Med. Chem. 2012, 55, 140-152.
76. McLuskey, K.; Gibellini, F.; Carvalho, P.; Avery, M.A.; Hunter, W.N. Inhibition of Leishmania major pteridine reductase by 2, 4, 6- triaminoquinazoline: Structure of the NADPH ternary complex. Acta Crystallogr. Sect. D 2004, D60, 1780-1785.
77. Schüttelkopf, A.W.; Hardy, L.W.; Beverley, S.M.; Hunter, W.N. Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design. J. Mol. Biol. 2005, 352, 105-116.
78. Cavazzuti, A.; Paglietti, G.; Hunter, W.N.; Gamarro, F.; Piras, S.; Loriga, M.; Allecca, S.; Corona, P.; McLuskey, K.; Tulloch, L.; et al. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc. Natl. Acad. Sci. USA 2008, 105, 1448-1453.
79. Venugopal, V.; Datta, A.K.; Bhattacharyya, D.; Dasgupta, D.; Banerjee, R. Structure of cyclophilin from Leishmania donovani bound to cyclosporin at 2.6 Å resolution: Correlation between structure and thermodynamic data. Acta Crystallogr. Sect. D 2009, D65, 1187-1195.
80. Arakaki, T.L.; Merritt, E.A.; Ullman, B.; Yates, P.A. Crystal structure of dihydroorotate dehydrogenase from Leishmania donovani. 2013, To be published, doi:10.2210/pdb3c61/pdb.
81. Kim, H.; Feil, I.K.; Verlinde, C.L.; Petra, P.H.; Hol, W.G. Crystal structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Leishmania mexicana: Implications for structure-based drug design and a new position for the inorganic phosphate binding site. Biochemistry 1995, 34, 14975-14986.
82. Choe, J.; Suresh, S.; Wisedchaisri, G.; Kennedy, K.J.; Gelb, M.H.; Hol, W.G. Anomalous differences of light elements in determining precise binding modes of ligands to glycerol-3- phosphate dehydrogenase. Chem. Biol. 2002, 9, 1189-1197.
83. Kedzierski, L.; Malby, R.L.; Smith, B.J.; Perugini, M.A.; Hodder, A.N.; Ilg, T.; Colman, P.M.; Handman, E. Structure of Leishmania mexicana phosphomannomutase highlights similarities with human isoforms. J. Mol. Biol. 2006, 363, 215-227.
84. Morgan, H.P.; McNae, I.W.; Nowicki, M.W.; Hannaert, V.; Michels, P.A.; Fothergill-Gilmore, L.A.; Walkinshaw, M.D. Allosteric mechanism of pyruvate kinase from Leishmania mexicana uses a rock and lock model. J. Biol. Chem. 2010, 285, 12892-12898.
85. Morgan, H.P.; McNae, I.W.; Nowicki, M.W.; Zhong, W.; Michels, P.A.; Auld, D.S.; Fothergill-Gilmore, L.A.; Walkinshaw, M.D. The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site. J. Biol. Chem. 2011, 286, 31232-31240.
86. Venkatesan, R.; Alahuhta, M.; Pihko, P.M.; Wierenga, R.K. High resolution crystal structures of triosephosphate isomerase complexed with its suicide inhibitors: The conformational flexibility of the catalytic glutamate in its closed, liganded active site. Protein Sci. 2011, 20, 1387-1397.
87. Hargrove, T.Y.; Wawrzak, Z.; Liu, J.; Nes, W.D.; Waterman, M.R.; Lepesheva, G.I. Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14α- demethylase (CYP51) from Leishmania infantum. J. Biol. Chem. 2011, 286, 26838-26848.
88. Ilari, A.; Baiocco, P.; Messori, L.; Fiorillo, A.; Boffi, A.; Gramiccia, M.; Di Muccio, T.; Coltti, G. A gold-containing drug against parasitic polyamine metabolism: The X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids 2012, 42, 803-811.
89. Baiocco, P.; Ilari, A.; Colotti, G.; Malatesta, F.; Fiorillo, A. Crystal structure of Leishmania infantum trypanothione reductase in complex with NADPH and trypanothione. To be published, doi:10.2210/pdb4adw/pdb.
90. Baiocco, P.; Ilari, A.; Colotti, G.; Biava, M. Structure of TR from Leishmania infantum in complex with a diarylpirrole-based inhibitor. To be published, doi:10.2210/pdb4apn/pdb.
91. Molegro Virtual Docker v 5.0. Molegro ApS: Aarhus, Denmark, 2011.
92. Thomsen, R.; Christensen, M.H. MolDock: A new technique for high-accuracy molecular docking. J. Med. Chem. 2006, 49, 3315-3321.
93. Spartan '10 for Windows, v 1.1. : Wavefunction, Inc.: Irvine, CA, USA, 2011.
94. Halgren, T.A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF 94. J. Comput. Chem. 1996, 17, 490-519.
95. Collaborative Computational Project, Number 4. The CCP4 suite: Program for protein crystallography. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 1994, 50, 760-763.
96. Stein, N. CHAINSAW: A program for mutating pdb files used as templates in molecular replacement. J. Appl. Crystallogr. 2008, 41, 641-643.
97. Brünger, A.T.; Adams, P.D.; Clore, G.M.; DeLano, W.L.; Gros, P.; Grosse-Kunstleve, R.W.; Jiang, J.S.; Kuszewski, J.; Nilges, M.; Pannu, N.S.; et al. Crystallography & NMR System: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 1998, 54, 905-921.